Cooley LLP announced today that it advised the underwriters on Epizyme, Inc.’s recent IPO. Epizyme, now trading on the NASDAQ Global Stock Market under the symbol “EPZM,” is a Massachusetts-based biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers.
Citigroup Global Markets Inc., Cowen and Company, LLC and Leerink Swann LLC acted as lead joint book-running managers for the offering. JMP Securities LLC and Wedbush Securities Inc. acted as co-managers.
The Cooley corporate securities team advising the underwriters was led by partners Drew Williamson and Brent Siler and also included special counsel Brian Leaf and associate Robert E. Jones. Partner Ken Krisko and associate Jen Raab advised on life sciences issues; intellectual property advice was provided by partner Carol Laherty and associate Mark Hayman; partners Natasha Leskovsek and Drew Gantt and associate David Sclar provided regulatory advice; and partner Susan Cooper Philpot advised on tax issues.
Based on the American Lawyer‘s 2012 Corporate Scorecard, Cooley served as issuer counsel on 40 total US equity offerings, ranking as the most active law firm advising issuers in the country. Cooley was also the third most active law firm advising underwriters on US IPOs.
